CCXAP upgrades Taizhou Huaxin Pharmaceutical Investment Co., Ltd.’s long-term credit rating to Ag-, with stable outlook. | News & Events | China Chengxin (Asia Pacific) Credit Ratings Company Limited

2025.6.3

CCXAP upgrades Taizhou Huaxin Pharmaceutical Investment Co., Ltd.’s long-term credit rating to Ag-, with stable outlook.

Hong Kong, 3 June 2025 -- China Chengxin (Asia Pacific) Credit Ratings Company Limited (“CCXAP”) has upgraded Taizhou Huaxin Pharmaceutical Investment Co., Ltd.’s (“Huaxin” or the “Company”) long-term credit rating from BBB_g+ to A_g-, reflecting our expectation of increasing government’s willingness to provide support. The rating outlook is stable.

Click HERE to download the press release.

CCXAP’s public ratings are available at www.ccxap.com (Rating Results) and may be distributed through media and other means. Methodology used in this rating is the Rating Methodology for China’s Local Infrastructure Investment and Financing Companies dated July 2022, available at www.ccxap.com (Rating Methodologies).